# US 6,730,792 B2 · β3 adrenergic agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,792 B2
- Document ID: US6730792B2
- Status: Granted
- Kind: B2
- Application number: 10/311,112
- Filed: 2002-12-13
- Published: 2003-10-09
- Granted: 2004-05-04
- Earliest claimed: 2000-07-13
- Assignees: Eli Lilly and Company
- Inventors: Britta Evers; Cynthia Darshini Jesudason; Rushad Eruch Karanjawala; David Michael Remick; Daniel Jon Sall; Miles Goodman Siegel; Wolfgang Stenzel; Russell Dean Stucky; John Arnold Werner
- Web page: https://patentgrep.com/patent/US6730792B2

## CPC

- C07D 207/333: Radicals substituted by oxygen or sulfur atoms
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/30: Oxygen atoms
- C07D 213/82: in position 3
- C07D 213/84: Nitriles
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 277/24: Radicals substituted by oxygen atoms
- C07D 333/16: by oxygen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0043: {Nose}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/02: Suppositories; Bougies; Bases therefor; {Ovules}(apparatus for making A61J3/08; devices for introducing into the body A61M31/00)
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a β3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

## Claims

### Claim 1

A compound of formula I:
wherein:
A1, A2 and A3 are carbon or nitrogen provided that only one of A1, A2 and A3 can be nitrogen;
Het is an optionally substituted, optionally benzofused 5 or 6 membered heterocyclic ring;
R1, R1a and R1b are independently H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 haloalkyl, or SO2(C1-C6 alkyl);
R2 is H or C1-C6 alkyl;
R3 is H or C1-C6 alkyl;
R4 is H or C1-C6 alkyl;
or R3 and R4 combine with the carbon to which both are attached to form a C3-C6 cyclic ring;
or R4 and X1 combine with the carbon to which both are attached to form a C3-C8 cyclic ring;
or R4 combines with X1, the carbon to which both are attached, and the phenyl group to which X1 is attached to form:
wherein:
n and m are independently 0, 1, 2, or 3 provided that the sum of n+m is ≦4 and that R3 is H;
X is OCH2, SCH2 or a bond;
X1 is a bond or a C1-C5 divalent hydrocarbon moiety;
X2 is O, S, NH, NHSO2, SO2NH, CH2 or a bond; and
X3 is optionally substituted phenyl or an optionally substituted 5 or 6 membered heterocyclic ring; or a pharmaceutical salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 wherein:
A1, A2 and A3 are carbon;
Het is optionally substituted one to three times independently with halo, hydroxy, oxo, cyano, nitro, phenyl, benzyl, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, COR8, CO2R8, CONR8R8, NR8R8, NHCO(C1-C4 alkyl), NHCO(phenyl), NHCO(benzyl), SR8, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2(NR8R8), OCO(C1-C4 alkyl), OCO2R8 or OCONR8R8;
R1, R1a and R1b are independently H, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, or SO2(C1-C4 alkyl);
R2 is H or C1-C4 alkyl;
R3 and R4 are independently H or C1-C4 alkyl;
or R3 and R4 combine with the carbon to which both are attached to form a C3-C6 cyclic ring;
or R4 and X1 combine with the carbon to which both are attached to form a C3-C8 cyclic ring;
or R4 combines with X1, the carbon to which both are attached, and the phenyl group to which X1 is attached to form:
X3 is optionally substituted one to three times independently with halo, hydroxy, oxo, cyano, nitro, phenyl, benzyl, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, COR8, CO2R8, CONR8R8, NR8R8, NHCO(C1-C4 alkyl), NHCO(phenyl), NHCO(benzyl), SR8, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2(NR8R8), OCO(C1-C4 alkyl), OCO2R8 or OCONR8R8; and
R8 is independently at each occurrence H or C1-C4 alkyl; or a pharmaceutical salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2 of the formula:
wherein:
Het is selected from furan; isothiazole; isoxazole; oxazole; and thiophene; wherein said Het moieties are optionally substituted once with fluorine, methyl, cyano, SO2NH2 or COCH3;
R3 and R4 are independently H or methyl;
X3 is phenyl, pyridyl or pyridazinyl wherein said X3 moieties are substituted once or twice with chloro, cyano, CONH2 or SO2CH3; or a pharmaceutical salt thereof.

### Claim 4 (depends on 3)

The compound of claim 3 wherein Het is thien-2-yl optionally substituted once with fluorine, methyl, cyano, SO2NH2 or COCH3; R3 and R4 are both methyl; and X3 is phenyl or pyridyl wherein said X3 moieties are substituted once with cyano or CONH2; or a pharmaceutical salt thereof.

### Claim 5 (depends on 4)

The compound of claim 4 wherein X3 is pyridyl substituted once with cyano or CONH2; or a pharmaceutical salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5 which is selected from the group consisting of:
or a pharmaceutical salt thereof.

### Claim 7

A compound of the formula:
or a pharmaceutical salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7 which is the hydrochloride salt.

### Claim 9 (depends on 7)

The compound of claim 7 which is the hemi-fumarate, benzoate, salicylate or R-mandelate salt.

### Claim 10 (depends on 3)

A method of treating obesity comprising administering to a patient in need thereof a compound of claim 3.

### Claim 11 (depends on 3)

A method of treating Type II Diabetes comprising administering to a patient in need thereof a compound of claim 3.

### Claim 12

A compound of formula II:
wherein:
A1, A2 and A3 are carbon or nitrogen provided that only one of A1, A2 and A3 can be nitrogen;
Het is an optionally substituted, optionally benzofused 5 or 6 membered heterocyclic ring;
R1 and R1a are independently H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C4 haloalkyl, or SO2(C1-C6 alkyl); or a salt thereof.

### Claim 13 (depends on 12)

The compound of claim 12 of the formula:
wherein:
Het is selected from benzothiophene; furan; isothiazole; isoxazole; oxazole; thiophene; and thiazole; wherein said Het moieties are optionally substituted once with fluorine, chlorine, methyl, cyano, SO2NH2 or COCH3; or a salt thereof.

### Claim 14 (depends on 1)

A process for preparing a compound of claim 1 which comprises reacting a compound of formula II:
with a compound of formula III:
in the presence of a suitable solvent.

### Claim 15 (depends on 7)

A method of treating obesity comprising administering to a patient in need thereof a compound of claim 7.

### Claim 16 (depends on 8)

A method of treating obesity comprising administering to a patient in need thereof a compound of claim 8.

### Claim 17 (depends on 9)

A method of treating obesity comprising administering to a patient in need thereof a compound of claim 9.
